Abstract
This study was first conducted to characterize the intravenous and oral pharmacokinetics of magnolin, a major pharmacologically active ingredient of Magnolia fargesii, at various doses in rats. Magnolin was administered to rats by intravenous injection (0.5, 1 and 2 mg/kg doses) and oral administration (1, 2 and 4 mg/kg doses), and serial plasma and urine samples were harvested. Magnolin concentrations were determined by a validated LC/MS/MS assay. After both intravenous and oral administration, the AUCs were linearly increased as the dose increased. Other pharmacokinetic parameters of magnolin (except the V ss after the intravenous administration) were also independent of the doses. The extent of absolute oral bioavailability ranged from 54.3–76.4% for the oral doses examined. Magnolin was considerably bound to rat plasma proteins and the binding value was constant (71.3–80.5%) over a concentration ranging from 500 to 10000 ng/mL. The pharmacokinetic parameters of magnolin were doseindependent after both intravenous and oral administration. When given orally, magnolin was rapidly absorbed.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Ahn, K. S., Jung, K. Y., Kim, J. H., Oh, S. R., and Lee, H. K., Inhibitory activity of lignan components from the flower buds of Magnoliae fargesii on the expression of cell adhesion molecules. Biol. Pharm. Bull., 24, 1085–1087 (2001).
Baek, J. A., Lee, Y. D., Lee, C. B., Go, H. K., Kim, J. P., Seo, J. J., Rhee, Y. K., Kim, A. M., and Na, D.J., Extracts of Magnoliae flos inhibit inducible nitric oxide synthase via ERK in human respiratory epithelial cells. Nitric Oxide, 20, 122–128 (2009).
Bhattaram, V. A., Graefe, U., Kohlert, C., Veit, M., and Derendorf, H., Pharmacokinetics and bioavailability of herbal medicinal products. Phytomedicine, 9(Suppl. 3), 1–33 (2002).
Chae, S. H., Kim, P. S., Cho, J. Y., Park, J. S., Lee, J. H., Yoo, E. S., Baik, K. U., Lee, J. S., and Park, M. H., Isolation and identification of inhibitory compounds on TNF-alpha production from Magnolia fargesii. Arch. Pharm. Res., 21, 67–69 (1998).
FDA/Center for Drug Evaluation and Research, Guidance for industry: Botanical drug products (2004). Available at: http://www.fda.gov/cder/guidance/index.htm.
Jung, K. Y., Kim, D. S., Oh, S. R., Park, S. H., Lee, I. S., Lee, J. J., Shin, D. H., and Lee, H. K., Magnone A and B, novel anti-PAF tetrahydrofuran lignans from the flower buds of Magnolia fargesii. J. Nat. Prod., 61, 808–811 (1998).
Kim, J. Y., Lim, H. J., Lee, D. Y., Kim, J. S., Kim, D. H., Lee, H. J., Kim, H. D., Jeon, R., and Ryu, J. H., In vitro anti-inflammatory activity of lignans isolated from Magnolia fargesii. Bioorg. Med. Chem. Lett., 19, 937–940 (2009a).
Kim, N. J., Oh, S. R., Lee, H. K., and Lee. H. S., Simultaneous determination of magnolin and epimagnolin A in rat plasma by liquid chromatography with tandem mass spectrometry: application to pharmacokinetic study of a purified extract of the dried flower buds of Magnolia fargesii, NDC-052 in rats. J. Pharm. Biomed. Anal., 50, 53–57 (2009b).
Lee, H. K., Jung, K. Y., Ahn, K. S., Oh, S. R., Lee, I. S., Park, S. H., Kim, J. H., Jang, H. W., and Hong, N. D. (inventors), Korea Institute of Science & Technology (assignee), New lignans isolated from Magnolia flos with leukotriene synthesis inhibitory activity. Korea Patent 10-0321313-0000 (2002).
Miyazawa, M., Kasahara, H., and Kameoka, H., Biotransformation of (+)-magnolin and (+)-yangabin in rat. Phytochemistry, 32, 1421–1424 (1993).
Shen, Y., Pang, E. C., Xue, C. C., Zhao, Z. Z., Lin, J. G., and Li, C. G., Inhibitions of mast cell-derived histamine release by different Flos Magnoliae species in rat peritoneal mast cells. Phytomedicine, 15, 808–814 (2008).
Tang, W. and Eisenbrand, G., Chinese Drugs of Plant Origin: Chemistry, Pharmacology and Use in Traditional and Modern Medicine. Springer-Verlag: Berlin (1992).
Zhao, W., Zhou, T., Fan, G., Chai, Y., and Wu, Y., Isolation and purification of lignans from Magnolia biondii Pamp by isocratic reversed-phase two-dimensional liquid chromatography following microwave-assisted extraction. J. Sep. Sci., 30, 2370–2381 (2007).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Kim, N.J., Song, W.Y., Yoo, S.D. et al. Pharmacokinetics of magnolin in rats. Arch. Pharm. Res. 33, 933–938 (2010). https://doi.org/10.1007/s12272-010-0617-3
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12272-010-0617-3